We can’t show the full text here under this license. Use the link below to read it at the source.
Development and characterization of a bivalent mRNA vaccine targeting the Delta and Omicron variants of SARS-CoV-2
Development and testing of an mRNA vaccine targeting both Delta and Omicron COVID-19 variants
AI simplified
Abstract
ARCoV-Biv induced mean neutralization titers (NT50) of 87,556.33 against Delta and 52,634.67 against Omicron BA.1.
- The bivalent targets the receptor-binding domains of the Delta and Omicron BA.1 variants.
- In vitro characterization indicated that ARCoV-Biv has favorable physicochemical properties similar to existing monovalent mRNA vaccines.
- Immunization with ARCoV-Biv under a two-dose regimen resulted in significant increases in responses compared to pre-booster levels.
- ARCoV-Biv enhanced neutralizing activity against multiple variants, including BA.2.12.1 and BA.4/5, following prior immunization with a prototype vaccine.
- Compared to mRNA-1273.214, ARCoV-Biv showed a higher breadth of neutralization against Delta and Omicron BA.1, as well as improved T-cell responses.
AI simplified
Key numbers
87,556.33
Increase in Titer against Delta
Mean neutralization titer against Delta after ARCoV-Biv booster.
52,634.67
Increase in Titer against Omicron BA.1
Mean neutralization titer against Omicron BA.1 after ARCoV-Biv booster.
5,700.67
Increase in Neutralization against BA.2.12.1
Neutralization titer against BA.2.12.1 after ARCoV-Biv booster.